



# TB Times

## Mayo Clinic Center for Tuberculosis (MCCT)

### UPCOMING EVENTS

Select links for details

[MCCT Innovations in  
TB:  
TB and Diabetes  
Mellitus](#)  
May 24, 2024  
Webinar

[TB Lunch and Learn  
Series](#)  
Select Thursdays  
Virtual


[2024 Civil Surgeons  
Webinar Series](#)  
June 20, 2024  
Webinar

[TB ETN and TB PEN  
Conference](#)  
September 17-19, 2024  
Atlanta, GA  
In-person

[TB Clinical Intensive](#)  
October 9-10, 2024  
Rochester, MN  
In-person

[Iowa TB Clinical  
Intensive](#)  
October 24-25, 2024  
Des Moines, IA  
In-person

[Bi-State Infectious  
Disease Conference](#)  
November 8, 2024  
St. Louis, Missouri  
In-person



## Good Times in Baltimore

The MCCT team recently attended the NTCA TB Conference in Baltimore, Maryland, where we had an enriching experience connecting with familiar faces and networking with individuals from our region. The conference offered a diverse range of presentations, providing valuable updates on TB-related topics. During a poster session led by James Gaensbauer, M.D., MScPH, we had the pleasure of engaging with colleagues as we discussed our collaborative approach to addressing a TB outbreak in Stearns County, MN. This conference was a fantastic opportunity to exchange ideas and engage with fellow professionals. Thank you to everyone involved in putting this amazing learning experience together!



## Summit Success!

The Wisconsin TB Summit was a resounding success, drawing in 409 learners throughout the month of April. The summit comprised five virtual sessions covering a wide range of topics crucial to TB management and prevention. A highlight was the inspiring personal stories shared by TB survivors. The summit concluded with an engaging "Ask the Expert" session. Sessions were recorded and are now available online at [Wisconsin TB Summit](#). A huge thank you goes out to the planning committee whose efforts made this event possible.

## TB Diagnostic Strategies Recording Available

In the April session of the **Innovations in TB** webinar series, our presenters, Nancy Wengenack, Ph.D. and Elitza Theel, Ph.D., discussed the latest advancements in TB diagnostic strategies, focusing on emerging tools, updates and the interpretation of the IGRA. You can view the recording on our [Self-Study Courses](#) webpage.




## New CDC Website Launch

The new CDC.gov site launches on the evening of May 15, 2024. While most of CDC's new content will be available at launch, some content will return in phases as it is improved. Learn more by reading the [New CDC.gov FAQ](#).



You may provide feedback now and after the new site launches by contacting [dcm@cdc.gov](mailto:dcm@cdc.gov). CDC is also offering a [Zoom webinar](#) after the launch about the new site. The webinar will be on Friday, May 17th at 1pm ET.



### Spotlight on MDR-TB

#### [Role of therapeutic drug monitoring in the treatment of multi-drug resistant tuberculosis](#)

This newly published article discusses the challenges posed by multi-drug resistant tuberculosis (MDR-TB) and the importance of therapeutic drug monitoring (TDM) in its treatment. MDR-TB requires prolonged therapy with second-line drugs, increasing the risk of toxicities and treatment failure. The article outlines the TDM process, pharmacokinetic parameters for MDR-TB drugs, and recommendations for dose adjustments based on TDM results.


#### [Multidrug-resistant tuberculosis in children: A practical update on epidemiology, diagnosis, treatment and prevention](#)

This article discusses the challenges in diagnosing and treating pediatric multidrug-resistant tuberculosis (MDR-TB), highlighting barriers to identification, confirmation, and safe treatment. Despite these challenges, recent advancements in diagnostics and treatment offer hope for improved outcomes. The article introduces two cases illustrating both the difficulties in managing MDR-TB in children and the potential for positive outcomes.

## FDA Issues Laboratory Developed Test (LDT) Rule

FDA considered the large volume of comments received on the notice of proposed rulemaking, and considering that input, has adjusted the phaseout policy in a manner that better serves the public health.

The FDA intends to exercise enforcement discretion regarding premarket review and most quality system requirements for certain categories of IVDs. [Read the full press release here.](#)



## New NTCA Isolation Guidelines

In April, the National Tuberculosis (TB) Coalition of America (NTCA, formerly the National TB Controllers Association) released new recommendations on public health practices related to respiratory isolation and restrictions (RIR) for persons with pulmonary TB (PWTB) in community settings (i.e., non-healthcare and non-congregate settings). Below you will find supporting documents that details these recommendations in detail.

- [Duration of Effective Tuberculosis Treatment, not Acid-Fast Bacilli \(AFB\) Smear Status, as the Determinant for Deisolation in Community Settings](#)
- [NTCA Guidelines for Respiratory Isolation and Restrictions to Reduce Transmission of Pulmonary TB in Community Settings](#)



## INNOVATIONS IN TUBERCULOSIS Webinar Series

**4<sup>th</sup> Friday of every month**

**[Learn More Here](#)**

This free monthly webinar series offers healthcare professionals the latest insights in tuberculosis (TB). Tuberculosis experts will discuss screening, diagnosis, and treatment of TB disease and latent TB infection (LTBI). Topics include considerations for pediatric and adult populations, clinical updates, diagnostic methods, and treatment strategies. Healthcare professionals managing patients with TB can stay informed on research developments and emerging treatment regimens for active TB and LTBI, exploring innovative approaches to enhance patient adherence and outcomes.

## Newsletter Content Suggestions

We invite you to be active participants in shaping the content of our newsletter. We will do our best to provide clarity on your TB related questions and include topics and events you would like to showcase. Simply submit your ideas to [TB Times Content Suggestion](#). Each issue we will feature suggested content, making this newsletter a true reflection of your needs.

## Vision

To become a regionally, nationally, and internationally recognized Center of Excellence for tuberculosis.

## Mission

To contribute, in a meaningful way, to the control, management, and elimination of tuberculosis regionally, nationally, and globally.



## Medical Consultation

MCCT provides expert medical consultation to public health and medical professionals in our assigned region. We have colleagues with expertise in public health nursing, pharmacy, laboratory, occupational health, pediatrics, and radiology just to name a few.

Consultations can be requested using one of the following options:

- Submit at [IDCrowd Platform](#)
- Email [tbcenter@mayo.edu](mailto:tbcenter@mayo.edu)
- Call 507-284-0275

IDCrowd is a new platform for submitting requests used by all TB COEs. If you are using IDCrowd for the first time, choose the option to register for a new membership. Additional information on how to submit a request can be found [here](#).

## Mini Fellowships

As part of the TB COE initiatives, MCCT is providing mini-fellowship opportunities for healthcare professionals seeking to deepen their understanding of TB.

Experiences will be curated to meet individual learning needs. Some experiences that may be offered include shadowing healthcare professionals as they interact with patients, observing directly observed therapy (DOT), and participating in TB case reviews.

You can find out more information by emailing [tbcenter@mayo.edu](mailto:tbcenter@mayo.edu). To be considered for a mini fellowship, please submit an [application here](#).

## Educational Requests

MCCT is able to support a variety of TB related needs including virtual and in-person training, educational material development, and technical assistance. Please contact us to discuss ways we can support your work in treating and preventing tuberculosis.

## Contact Us



[TBcenter@mayo.edu](mailto:TBcenter@mayo.edu)



[centerfortuberculosis.mayo.edu](https://centerfortuberculosis.mayo.edu)



507-284-0275